Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA greenlights Jesduvroq, which GSK hails as ‘first innovative medicine’ for anemia in three decades

By Brian Buntz | February 2, 2023

GSKGSK (NYSE:GSK) has received FDA approval for Jesduvroq, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a daily treatment for anemia associated with chronic kidney disease in adult dialysis patients.

Jesduvroq is the first new medicine for anemia treatment in over 30 years, GSK noted.

The drug is the only HIF-PHI to win FDA approval.

Black box warning

A black box warning, however, may constrain its use. The warning notes that Jesduvroq may lead to an increased risk of death, heart attack and other cardiovascular problems. In addition, the warning notes that the drug may elevate the risk of blood clotting problems and major heart events. The FDA recommends that the drug be used only at the lowest dose to minimize the need for blood transfusions.

Barclays estimated Jesduvroq sales to top out at £364 million ($450 million).

GSK shares ticked down one percentage point to $35.13 after announcing the approval news.

HIF-PHIs offer promise for correcting anemia

HIF-PHIs target prolyl hydroxylase enzymes that regulate the hypoxia-inducible factors (HIFs) pathway. Inhibiting these enzymes stabilizes HIFs and promotes gene transcription in correcting anemia.

A report in the journal Kidney noted that HIF-PHIs show promise in maintaining hemoglobin levels in patients with both non-dialysis- and dialysis-dependent CKD.

FDA based on the Jesduvroq approval on data from the pivotal ASCEND-D study.

The trial found that Jesduvroq was non-inferior to erythropoiesis-stimulating agents regarding the change in hemoglobin level from baseline and cardiovascular outcomes.

CKD affects around 700 million patients worldwide, with an estimated one in seven developing anemia.

In October 2022, GSK announced that FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted in favor of daprodustat in adult dialysis patients with anemia of CKD with a 13 to 3 vote. However, the committee did not recommend the drug for adult non-dialysis patients with anemia of CKD.

Jesduvroq is currently under review with the European Medicines Agency, with a decision expected in 2023.


Filed Under: Nephrology/urology
Tagged With: Jesduvroq
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Illustration of the thought processes in the brain
From gene therapy to vaccines to mitochondrial rescue, the quest for more effective neurodegenerative therapies faces mixed outcomes in 2024
hemodialysis in people on the equipment
Beyond diabetes and obesity: Can GLP-1 therapies also transform chronic disease treatment?
Novo Nordisk in the Drug Discovery & Development Pharma 50
Novo Nordisk stops once-weekly semaglutide kidney outcomes trial early following interim analysis
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly gets FDA review for empagliflozin in chronic kidney disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE